Connect with us

Hi, what are you looking for?

Investing

ImmunityBio stock loses more than half its value after disclosing FDA can’t approve the BLA for its cancer treatment in its present form

Shares of ImmunityBio Inc.
IBRX,
-55.14%
plummeted 53.7% toward a record one-day selloff in premarket trading Thursday, after the immunotherapy company disclosed it received a “complete response letter” from the U.S. Food and Drug Administration, but puts the company’s Biologics License Application (BLA) for its bladder cancer treatment Anktiva (N-803) on hold. The FDA determined that it can’t approve the BLA in its present form as a pre-license inspection of the company’s third-party contract manufacturer found deficiencies. “The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible,” ImmunityBio said in a statement. Separately, ImmunityBio’s Executive Chairman Patrick Soon-Shiong agreed to provide $30 million in non-convertible debt financing, and the company said it was exploring partnering with a large biopharmaceutical company for commercialization of N-803. The stock’s current record selloff on a closing basis is 27.9% on Jan. 14, 2020. The selloff comes after the stock has nearly tripled in the past couple weeks, after the company announced the opening of a clinical trial to study its Tri-Ad5 cancer vaccines plus N-803 to prevent cancer in people with Lynch syndrome. The stock has rallied 22.7% year to date through Wednesday, while the iShares Biotechnology exchange-traded fund
IBB,
-0.46%
has slipped 0.2% and the S&P 500
SPX,
-0.17%
has gained 7.8%.

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Videos

Watch full video on YouTube

Videos

Watch full video on YouTube